Literature DB >> 11901219

Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene.

Christine Börner1, Volker Höllt, Jürgen Kraus.   

Abstract

mu-Opioid receptors mediate such opioid effects as analgesia, euphoria, and immunomodulation. Gene expression of mu-opioid receptors can be modulated by various substances, including cytokines, hormones, and drugs. Some of these stimuli (e.g., IL-1beta and cocaine) have been shown to activate members of the AP-1 transcription factor family. In addition, transcription of the mu-opioid receptor gene is induced by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C, which in turn is an activator of AP-1 transcription factors. This indicates that signaling pathways involving protein kinase C and activator protein 1 (AP-1) transcription factors are important for the specific expression pattern of the mu-opioid receptor gene. In this report, we show that TPA activates AP-1 as well as the transcription factor nuclear factor kappaB (NFkappaB) in the mu-opioid receptor expressing neuroblastoma cell line SH SY5Y. In transfection experiments performed in these cells, both factors trans-activate expression of reporter gene constructs containing the human mu-opioid receptor gene promoter. By excluding the effects of TPA on NFkappaB with the specific NFkappaB inhibitor sulfasalazine, AP-1 regulatory elements were localized. Two AP-1 elements, which differ in one nucleotide each from the classic AP-1 binding site, were delineated to positions -2388 and -1434 of the promoter. Independent of their orientation, these elements conferred TPA responsiveness on the heterologous thymidine kinase promoter. AP-1 binding to these elements was confirmed using electrophoretic mobility shift and immunoshift assays.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901219     DOI: 10.1124/mol.61.4.800

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

Review 1.  Transcriptional and epigenetic regulation of opioid receptor genes: present and future.

Authors:  Li-Na Wei; Horace H Loh
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

2.  Sex differences in μ-opioid receptor expression in trigeminal ganglia under a myositis condition in rats.

Authors:  X Zhang; Y Zhang; J Asgar; K Y Niu; J Lee; K S Lee; M Schneider; J Y Ro
Journal:  Eur J Pain       Date:  2013-06-25       Impact factor: 3.931

3.  Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation.

Authors:  D Philippe; D Chakass; X Thuru; P Zerbib; A Tsicopoulos; K Geboes; P Bulois; M Breisse; H Vorng; J Gay; J-F Colombel; P Desreumaux; M Chamaillard
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

4.  Dual regulation of mu opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1β: evidence for opioid-immune crosstalk.

Authors:  Shekher Mohan; Randall L Davis; Udaya DeSilva; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2010-07-07       Impact factor: 3.478

5.  A role for reactive oxygen species in endotoxin-induced elevation of MOR expression in the nervous and immune systems.

Authors:  Erik F Langsdorf; Xin Mao; Sulie L Chang
Journal:  J Neuroimmunol       Date:  2011-06-17       Impact factor: 3.478

6.  Changes in intramuscular cytokine levels during masseter inflammation in male and female rats.

Authors:  Katelyn Y Niu; Jin Y Ro
Journal:  Neurosci Lett       Date:  2010-10-20       Impact factor: 3.046

7.  micro-Opioid receptor activation prevents acute hepatic inflammation and cell death.

Authors:  Dania Chakass; David Philippe; Edmone Erdual; Sébastien Dharancy; Mathilde Malapel; Caroline Dubuquoy; Xavier Thuru; Jerome Gay; Claire Gaveriaux-Ruff; Pierre Dubus; Philippe Mathurin; Brigitte L Kieffer; Pierre Desreumaux; Mathias Chamaillard
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

8.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Authors:  Gabor Oroszi; Raymond F Anton; Stephanie O'Malley; Robert Swift; Helen Pettinati; David Couper; Qiaoping Yuan; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

9.  Single nucleotide variants of the TGACTCA motif modulate energetics and orientation of binding of the Jun-Fos heterodimeric transcription factor.

Authors:  Kenneth L Seldeen; Caleb B McDonald; Brian J Deegan; Amjad Farooq
Journal:  Biochemistry       Date:  2009-03-10       Impact factor: 3.162

Review 10.  Epigenetics: a promising paradigm for better understanding and managing pain.

Authors:  Seungmae Seo; Adrienne Grzenda; Gwen Lomberk; Xiao-Ming Ou; Ricardo A Cruciani; Raul Urrutia
Journal:  J Pain       Date:  2013-04-19       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.